NCT02314169 2026-04-22
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
2,157 trialsNCT03181867 2026-04-22
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03210714 2026-04-22
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03436654 2026-04-22
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04049331 2026-04-22
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
Seattle Institute for Biomedical and Clinical Research
Phase 2 Active not recruiting
NCT04080804 2026-04-22
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT04123366 2026-04-22
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04452955 2026-04-22
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT04530552 2026-04-22
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04701307 2026-04-22
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04837820 2026-04-22
The Effect of Acupuncture on Cancer-Related Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04917809 2026-04-22
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05507541 2026-04-22
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Phase 2 Active not recruiting
NCT05596409 2026-04-22
ELCIN
Stemline Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05638295 2026-04-22
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06027268 2026-04-22
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06637501 2026-04-22
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2 Active not recruiting
NCT02398773 2026-04-21
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02782949 2026-04-21
Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02957968 2026-04-21
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Phase 2 Active not recruiting
NCT03149029 2026-04-21
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03389477 2026-04-21
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT03660826 2026-04-21
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04001829 2026-04-21
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04414163 2026-04-21
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
ImmuneOncia Therapeutics Inc.
Phase 2 Active not recruiting
NCT04968106 2026-04-21
TORNADO
Institut Bergonié
Phase 2 Active not recruiting
NCT05009069 2026-04-21
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05308446 2026-04-21
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05445843 2026-04-21
KontRASt-06
Novartis
Phase 2 Active not recruiting
NCT05480384 2026-04-21
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Phase 2 Active not recruiting
NCT05761171 2026-04-21
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT05836571 2026-04-21
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05836584 2026-04-21
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06167291 2026-04-21
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06284564 2026-04-21
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06336291 2026-04-21
GLIOSTELLA
Philogen S.p.A.
Phase 2 Active not recruiting
NCT06357988 2026-04-21
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07047118 2026-04-21
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT07541001 2026-04-21
China Phase II
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT00092222 2026-04-20
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03076554 2026-04-20
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03441113 2026-04-20
Extended Access of Momelotinib in Adults With Myelofibrosis
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03485209 2026-04-20
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT03820141 2026-04-20
DTP
The Methodist Hospital Research Institute
Phase 2 Active not recruiting
NCT04028063 2026-04-20
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Phase 2 Active not recruiting
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT04393350 2026-04-20
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
NCT04561492 2026-04-20
PentiMyelo
Nantes University Hospital
Phase 2 Active not recruiting